Partitioning of time trends in prevalence and mortality of bladder cancer in the United States

Akushevich, Igor; Yashkin, Arseniy; Inman, Brant A.; Sloan, Frank A.

doi:10.1016/j.annepidem.2020.05.006

Cited by 9 publications

(15 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Using partitioning approach [11,12], we quantitatively evaluated contributions of cancer incidence, relative survival, and early-stage diagnoses to the changes in cancer prevalence in older U.S. population aged 65+. In this study, partitioning of prevalence was analyzed together with empiric patterns of cancer incidence and stage-specific relative survival thus providing more detailed information on the mechanisms of changes in prevalence of various cancers in the U.S. For all studied cancers, growth of prevalence decelerated over time and for cancers of colon, urinary bladder, ovaries, and prostate, the prevalence passed its respective maximum resulting in declines over recent years.…”

Section: Discussionmentioning

confidence: 99%

“…Weibull model for relative survival was parameterized in terms of  and  exactly as described in refs. [11,12] for all cancer sites except of cancers of prostate and breast, and skin melanoma for which we used the model in terms of  and  . The latter model allows for relative survival for certain cancer sites exceeding 100% (or >1.00): i.e., when survival of patients with certain early-stage cancers was better than survival of individuals in general U.S. population aged 65+, that is observed for these cancer sites.…”

Section: Partitioning Analysismentioning

confidence: 99%

“…Slowing improvement or even decline in relative survival detected for several cancers (e.g., bladder, liver, ovarian) in our study can be the result of the accumulation of delayed mortality in individuals diagnosed early in the study timeperiod and benefiting from improved survival at the time of their diagnosis. Targeted partitioning of cancer mortality [12] would be required to further analyze this hypothesis.…”

Section: Dynamics Of Cancer Incidence and Its Role In Cancer Prevalen...mentioning

confidence: 99%

“…This could be partially due to the complexity of interpretating prevalence trends which result from three distinct interrelated processes: dynamics in cancer incidence, survival, and the average stage at time of diagnosis. The partitioning analysis [9][10][11][12] used in this study, generates models of cancer prevalence, incidence, survival and stage ascertainment and then provides quantitative estimates of the relative fractions of the contributions of the above components to the total change in cancer prevalence. Together, changes in the relative magnitudes of these components provide a quantitative picture describing the epidemiologic causes of prevailing prevalence trends and how these have changed over time in response to changes in screening, treatment and exposure to risk-related factors (e.g., smoking, asbestos exposure etc.).…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Underlying the mechanisms of changes in cancer prevalence among the U.S. Medicare beneficiaries: contributions of incidence, survival, and ascertainment at early stages.

Akushevich

Yashkin

Kovtun³

et al. 2022

Preprint

Self Cite

View full text Add to dashboard Cite

Purpose: To quantitatively evaluate contributions of trends in incidence, relative survival, and stage at diagnosis to the dynamics in the prevalence of major cancers (lung, prostate, colon, breast, urinary bladder, ovaries, stomach, pancreas, esophagus, kidney, liver, and skin melanoma) among older U.S. adults age 65+. Methods: Trend partitioning was applied to the Surveillance, Epidemiology, and End Results Program data for 1973-2016. Results: Growth of cancer prevalence in older adults decelerated or even decreased over time for all studied cancers due to decreasing incidence and improving survival for most of cancers, with a smaller contribution of the stage at cancer diagnosis. Changes in prevalence of cancers of lung, colon, stomach, and breast were predominantly due to decreasing incidence, increasing survival and more frequent diagnoses at earlier stages. Changes in prevalence of some other cancers demonstrated adverse trends such as decreasing survival in localized and regional stages (urinary bladder and ovarian) and growing impact of late-stage diagnoses (esophageal cancer). Conclusion: While decelerating or decreasing prevalence of many cancers were due to a beneficial combination of decreasing incidence and increasing survival, there are cancers for which decelerating prevalence is due to the lack of improvement in their stage-specific survival and/or increasing frequency of diagnosis at advanced stages. Overall, if the observed trends persist, it is likely that cancer burden due to its prevalence in older U.S. population will be lower than it was projected in earlier studies.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Partitioning Analysismentioning

confidence: 99%

Section: Dynamics Of Cancer Incidence and Its Role In Cancer Prevalen...mentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Underlying the mechanisms of changes in cancer prevalence among the U.S. Medicare beneficiaries: contributions of incidence, survival, and ascertainment at early stages.

Akushevich

Yashkin

Kovtun³

et al. 2022

Preprint

Self Cite

View full text Add to dashboard Cite

show abstract

“…Bladder cancer is one of the most common malignant tumors of the urinary system, affecting about 430,000 patients and killing about 165,000 patients annually. 1 , 2 Despite the fact that the current clinical stages and histopathologic classification for bladder cancer employ widely used prognostic tools, key points with regard to the prediction about recurrence and metastasis of bladder cancer remain unclear. 3 – 6 Therefore, it is necessary to explore the molecular mechanisms of bladder cancer occurrence and development to identify novel prognostic biomarkers and potential therapeutic targets.…”

Section: Introductionmentioning

confidence: 99%

Immunotherapeutic Significance of a Prognostic Alternative Splicing Signature in Bladder Cancer

Chen

Liao

et al. 2022

Technol Cancer Res Treat

View full text Add to dashboard Cite

Objectives: Bladder cancer is the fourth most common malignancy in men in the United States. Aberrant alternative splicing (AS) events are involved in the carcinogenesis, but the association between AS and bladder cancer remains unclear. This study aimed to construct an AS-based prognostic signature and elucidate the role of the tumor immune microenvironment (TIME) and the response to immunotherapy and chemotherapy in bladder cancer. Methods: Univariate Cox regression analysis was performed to detect prognosis-related AS events. The least absolute shrinkage and selection operator (LASSO) and multivariate Cox analyses were employed to build prognostic signatures. Kaplan–Meier survival analysis, multivariate Cox regression analysis, and receiver operating characteristic (ROC) curves were conducted to validate the prognostic signatures. Then, the Estimation of Stromal and Immune cells in MAlignant Tumor tissues using Expression data (ESTIMATE) and tumor immune estimation resource (TIMER) databases were searched and the single-sample gene set enrichment analysis (ssGSEA) algorithm and CIBERSORT method were performed to uncover the context of TIME in bladder cancer. The Tumor Immune Dysfunction and Exclusion (TIDE) web tool and pRRophetic algorithm were used to predict the response to immunotherapy and chemotherapy. Finally, we constructed a correlation network between splicing factors (SFs) and survival-related AS events. Results: A total of 4684 AS events were significantly associated with overall survival in patients with bladder cancer. Eight prognostic signatures of bladder cancer were established, and a clinical survival prediction model was built. In addition, the consolidated prognostic signature was closely related to immune infiltration and the response to immunotherapy and chemotherapy. Furthermore, the correlation identified EIF3A, DDX21, SDE2, TNPO1, and RNF40 as hub SFs, and function analysis found ubiquitin-mediated proteolysis is correlated most significantly with survival-associated AS events. Conclusion: Our findings highlight the prognostic value of AS for patients with bladder cancer and reveal pivotal players of AS events in the context of TIME and the response to immunotherapy and chemotherapy, which may be important for patient management and treatment.

show abstract

Underlying mechanisms of change in cancer prevalence in older U.S. adults: contributions of incidence, survival, and ascertainment at early stages

Akushevich

Yashkin

Kovtun

et al. 2022

Cancer Causes Control

View full text Add to dashboard Cite

Purpose To quantitatively evaluate contributions of trends in incidence, relative survival, and stage at diagnosis to the dynamics in the prevalence of major cancers (lung, prostate, colon, breast, urinary bladder, ovaries, stomach, pancreas, esophagus, kidney, liver, and skin melanoma) among older U.S. adults age 65 +. Methods Trend partitioning was applied to the Surveillance, Epidemiology, and End Results Program data for 1973–2016. Results Growth of cancer prevalence in older adults decelerated or even decreased over time for all studied cancers due to decreasing incidence and improving survival for most of cancers, with a smaller contribution of the stage at cancer diagnosis. Changes in the prevalence of cancers of the lung, colon, stomach, and breast were predominantly due to decreasing incidence, increasing survival and more frequent diagnoses at earlier stages. Changes in prevalence of some other cancers demonstrated adverse trends such as decreasing survival in localized and regional stages (urinary bladder and ovarian) and growing impact of late-stage diagnoses (esophageal cancer). Conclusion While decelerating or decreasing prevalence of many cancers were due to a beneficial combination of decreasing incidence and increasing survival, there are cancers for which decelerating prevalence is due to lack of improvement in their stage-specific survival and/or increasing frequency of diagnosis at advanced stages. Overall, if the observed trends persist, it is likely that the burden associated with cancer prevalence in older U.S. adults will be lower comparing to projections based on constant increasing prevalence have previously estimated.

show abstract

Partitioning of time trends in prevalence and mortality of bladder cancer in the United States

Cited by 9 publications

References 18 publications

Underlying the mechanisms of changes in cancer prevalence among the U.S. Medicare beneficiaries: contributions of incidence, survival, and ascertainment at early stages.

Underlying the mechanisms of changes in cancer prevalence among the U.S. Medicare beneficiaries: contributions of incidence, survival, and ascertainment at early stages.

Immunotherapeutic Significance of a Prognostic Alternative Splicing Signature in Bladder Cancer

Underlying mechanisms of change in cancer prevalence in older U.S. adults: contributions of incidence, survival, and ascertainment at early stages

Contact Info

Product

Resources

About